EMCDDA–Europol Joint Report on a new psychoactive substance: N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide (4-fluoroisobutyrylfentanyl; 4F-iBF). by unknown
IS
S
N
 1
9
7
7
-7
8
6
8
EMCDDA–Europol Joint Report on a new psychoactive 
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In accordance with Article 5 of Council Decision 2005/387/JHA on 
the information exchange, risk assessment and control of new 
psychoactive substances 
About this series
EMCDDA–Europol Joint Report publications examine the detailed information 
provided by the EU Member States on individual new psychoactive substances. 
Information is collected from the Reitox network, the Europol National Units and the 
national competent authorities of the European Medicines Agency.
Each Joint Report serves as the basis upon which the decision to conduct a risk 
assessment of the new psychoactive substance is taken. It is part of the three-step 
procedure involving information exchange, risk assessment and decision-making in the 
framework of Council Decision 2005/387/JHA.
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I 1. Introduction
Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter 
the ‘Council Decision’) stipulates that ‘Where Europol and the 
EMCDDA, or the Council, acting by a majority of its members, 
consider that the information provided by the Member State 
on a new psychoactive substance merits the collection of 
further information, this information shall be collated and 
presented by Europol and the EMCDDA in the form of a Joint 
Report.’ The Joint Report shall be submitted to the Council of 
the European Union, the European Medicines Agency (EMA) 
and the European Commission.
In March 2017, the EMCDDA and Europol examined the 
available information on the new psychoactive substance 
N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)
isobutyramide, commonly known as 4-fluoroisobutyrylfentanyl 
(4F-iBF), through a joint assessment based upon the following 
criteria:
1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information 
collected on 4-fluoroisobutyrylfentanyl satisfied criteria 4 and 
6. The two agencies therefore concluded that sufficient 
information had been accumulated to merit the production of 
a Joint Report on 4-fluoroisobutyrylfentanyl as stipulated by 
Article 5.1 of the Council Decision.
I 2. Information collection process
In compliance with the provisions of the Council Decision, on 
25 April 2017 the EMCDDA and Europol launched a procedure 
for the collection of information on 4-fluoroisobutyrylfentanyl, 
in order to prepare the Joint Report. The information was 
collected mainly through the Reitox national focal points in the 
Member States, Turkey and Norway as well as the Europol 
National Units. In addition, the EMA collected information 
through the national competent authorities responsible for 
human and veterinary medicinal products in the Member 
States as well as in Norway, Iceland and Liechtenstein. The 
EMA also provided information as relevant to the centralised 
procedure for authorising medicinal products. The information 
collection process was largely concluded by 6 June 2017.
(1) OJ L 127, 20.5.2005, p. 32.
Information collected by Europol
Europol asked the Europol National Units to provide 
information on:
 ¡ the level of production of 4-fluoroisobutyrylfentanyl in their 
country;
 ¡ the level of distribution of 4-fluoroisobutyrylfentanyl in their 
country;
 ¡ the level of trafficking of 4-fluoroisobutyrylfentanyl in their 
country, both for internal, transit or export purposes;
 ¡ the number of seizures of 4-fluoroisobutyrylfentanyl in their 
country, the total amount of the seizures, country of origin, 
details on the physical forms (including photos);
 ¡ the role of organised crime or criminal groups, in the 
production, distribution and trafficking of 
4-fluoroisobutyrylfentanyl in their country; and,
 ¡ any known aspect of violence and/or money laundering 
relating to the production and trafficking of 
4-fluoroisobutyrylfentanyl.
Europol received responses from 16 Member States (2).
Information collected by the EMA
According to Article 5.3 of the Council Decision, the EMA 
requested that the national competent authorities responsible 
for human and veterinary medicinal products in the Member 
States, Norway, Iceland and Liechtenstein, provide information 
on whether:
 ¡ the new psychoactive substance 4-fluoroisobutyrylfentanyl 
has obtained a marketing authorisation;
 ¡ the new psychoactive substance 4-fluoroisobutyrylfentanyl 
is the subject of an application for a marketing 
authorisation;
 ¡ a marketing authorisation that had been granted in respect 
of the new psychoactive substance 
4-fluoroisobutyrylfentanyl has been suspended.
Twenty-three countries provided a response to the EMA’s 
request regarding human and/or veterinary medicinal 
products (3). The EMA also provided information as relevant to 
the centralised procedure for authorising human and 
veterinary medicinal products.
(2) In alphabetical order: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech 
Republic, Finland, Germany, Greece, Latvia, Lithuania, Luxembourg, Romania, 
Slovakia, Slovenia and Spain.
(3) Austria, Belgium, Denmark, Estonia, Finland, Germany, Greece, Ireland, Latvia, 
Norway, Poland, Spain, Sweden and the United Kingdom provided a response in 
relation to human and veterinary medicinal products. Croatia, Czech Republic, 
Hungary, Italy and the Netherlands provided a response in relation to human 
medicinal products. France, Portugal, Slovakia and Slovenia provided a response 
in relation to veterinary medicinal products.
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Furthermore, in anticipation of Article 7.3 of the Council 
Decision in relation to the manufacturing of medicinal 
products in the European Union, the EMA also requested 
information on whether the new psychoactive substance 
4-fluoroisobutyrylfentanyl is used to manufacture a medicinal 
product:
 ¡ which has been granted a marketing authorisation;
 ¡ for which an application has been made for a marketing 
authorisation;
 ¡ for which a marketing authorisation has been suspended 
by a competent authority.
Twenty-three countries (4) provided a response to the EMA’s 
request in this regard. The EMA also provided information as 
relevant to the centralised procedure for authorising human 
and veterinary medicinal products.
Information collected by the EMCDDA
The EMCDDA collected information through:
 ¡ a structured questionnaire to the Reitox national focal 
points. The EMCDDA received replies from 27 Member 
States (5), as well as Turkey and Norway;
 ¡ reports previously provided to the European Union Early 
Warning System, including EMCDDA–Europol Reporting 
Forms and Progress Reports and Final Reports;
 ¡ routine monitoring of open source information;
 ¡ a specific information request to the World Health 
Organization on whether or not 4-fluoroisobutyrylfentanyl is 
under assessment by the United Nations system;
 ¡ a search of open source information conducted specifically 
for the production of the Joint Report which included: 
scientific and medical literature, official reports, grey 
literature, internet drug discussion forums and related 
websites (hereafter, ‘user websites’) and, online vendors 
selling 4-fluoroisobutyrylfentanyl.
Thus, the information included in sections 3.2.1 and 3.3 of the 
Joint Report was provided by Europol, while the EMCDDA 
provided information included in sections 3.1, 3.2.2, 3.4, 3.5, 
3.6, 3.7, 3.8.1, 3.8.2 and 3.8.3 (in part). The information 
included in section 3.8.3 (in part) and section 4 was provided 
by the EMA.
(4) Austria, Belgium, Denmark, Estonia, Finland, Germany, Greece, Ireland, Latvia, 
Norway, Poland, Spain, Sweden and the United Kingdom provided a response in 
relation to human and veterinary medicinal products. Croatia, Czech Republic, 
Hungary, Italy and the Netherlands provided a response in relation to human 
medicinal products. France, Portugal, Slovakia and Slovenia provided a response 
in relation to veterinary medicinal products.
(5) A reply was not received from Slovakia. 
 3.  Information required by Article 5.2 
of the Council Decision
The order and titles of subsections 3.1 to 3.8 and section 4, 
below, are as they appear in Article 5.2(a) to (h) and Article 
5.3(a) to (c) of the Council Decision; sections are cross-
referenced with those set down in the Council Decision.
 3.1  Chemical and physical description, including 
the names under which the new psychoactive 
substance is known (Article 5.2(a) of 
the Council Decision)
Chemical description and names
4-Fluoroisobutyrylfentanyl (4F-iBF) belongs to the 
4-anilidopiperidine class of synthetic opioids. This class also 
includes fentanyl (6), which is internationally controlled and 
a number of other fentanils.
A total of fifteen fentanils are controlled under the United 
Nations Single Convention on Narcotic Drugs, 1961, as 
amended by the 1972 Protocol (7).
4-Fluoroisobutyrylfentanyl differs from fentanyl due to the 
presence of a fluorine atom on the anilido phenyl ring and also 
due to the presence of an isobutyramide group in place of the 
propanamide group present in fentanyl.
4-Fluoroisobutyrylfentanyl is the positional iso isomer of 
4-fluoro-butyrfentanyl (4F-BF) and thus both substances are 
structurally very closely related and they have the same 
molecular formula and molecular mass.
The molecular structure, molecular formula and molecular 
mass of 4-fluoroisobutyrylfentanyl are provided in in Figure 1.
(6) N-phenyl-N-[1-(2-phenylethyl)piperidin-4-yl]acetamide. 
(7) 3-Methylfentanyl, 3-methylthiofentanyl, acetyl-alpha-methylfentanyl, 
alpha-methylfentanyl, alpha-methylthiofentanyl, beta-hydroxy-3-methylfentanyl, 
beta-hydroxyfentanyl, para-fluorofentanyl, thiofentanyl, acetylfentanyl and 
butyrfentanyl are controlled under Schedule I and IV; alfentanil, fentanyl, 
sufentanil and remifentanil are controlled under Schedule I.
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The synthesis of 4-fluoroisobutyrylfentanyl was first described 
in a study which included 23 other fentanyl-related 
compounds (Ohta et al., 1999).
Commonly used names:  
4-fluoroisobutyrylfentanyl or 4F-iBF
Systematic (IUPAC) name:  
N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)
isobutyramide
Other chemical names:  
N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)piperidin-4- 
yl]propanamide;  
N- (4- fluorophenyl) - 2- methyl- N- [1- (2- phenylethyl) - 4- 
piperidinyl] propanamide;  
N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)-4-piperidyl]
propanamide;  
N-(4-Fluorophenyl)-N-(1-phenethyl-4-piperidinyl)
isobutyramide;  
N-(4-fluorophenyl)-N-(1-phenethylpiperidin-4-yl) 
isobutyramide;   
N-[1-(2-fenyletyl)piperidin-4-yl]-N-(4-fluorofenyl)-2-
metylpropanamid (Swedish)
Other names and code names:  
4-fluoro-isobutyrylfentanyl, 4-fluoro-isobutyrfentanyl, 
4-fluoro-isobutrylfentanyl, 4-F-iBF, 4-FiBF, 4-FIBF, FIBF, 
p-FIBF, p-FiBF
Chemical Abstracts Service (CAS) registry numbers (8): 
244195-32-2
(8) The Chemical Abstract Service Registry Number (CAS RN) is a unique 
numeric identifier assigned by the Chemical Abstract Service Division of the 
American Chemical Society to a specific, single chemical substance.
IUPAC International Chemical Identifier Key (InCHI Key) (9):  
OZDOSQNUJIXEOR-UHFFFAOYSA-N
The REACH registered substances database hosted by the 
European Chemicals Agency (ECHA) was searched using the 
CAS registry numbers listed above. The searches returned no 
hits.
Physical description
4-Fluoroisobutyrylfentanyl contains one basic nitrogen atom 
in the piperidine ring which can readily form salts with organic 
or inorganic acids.
There is no solubility data on 4-fluoroisobutyrylfentanyl or its 
hydrochloride salt; due to its similarity to fentanyl, the free 
base could be expected to be sparingly soluble in water; the 
hydrochloride and citrate salt could be expected to have 
greater aqueous solubility.
4-Fluoroisobutyrylfentanyl is expected to be lipophilic.
4-Fluoroisobutyrylfentanyl has been typically seized as 
a powder, in tablet form and as a liquid. A more detailed 
description of seizures and collected samples can be found in 
section 3.2.1 and section 3.2.2.
Detection and analysis
Methods documented in the literature for the detection of 
4-fluoroisobutyrylfentanyl and/or its metabolites include: 
liquid chromatography high–resolution mass spectrometry 
(LC-HRMS) (Watanabe et al., 2017; Helander et al., 2017); 
(9) InChI Key is a unique, non-proprietary stuctural identifier of chemical 
substances useful in electronic sources.
FIGURE 1 
Molecular structure, molecular formula and molecular mass of 4-fluoroisobutyrylfentanyl. Information on 4-fluoro-butyrfentanyl 
and fentanyl is provided for comparison.
N
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N
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F N
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O
4-fluoroisobutyrylfentanyl 4-fluoro-butyrfentanyl fentanyl
Molecular formula C23H29FN2O C23H29FN2O C22H28N2O
Molecular mass 368.50 368.50 336.48
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high performance liquid chromatography time-of-flight 
(HPLC-TOF) (Watanabe et al., 2017); gas chromatography–
mass spectrometry (GC-MS), HPLC-TOF, Fourier transform 
infrared spectroscopy attenuated total reflectance (FTIR-
ATR), gas chromatography–mass spectrometry–infrared 
(GC-MS-IR) condensed phase and nuclear magnetic 
resonance spectrometry (NMR) (Slovenian National Forensic 
Laboratory, 2016).
Chromatographic and spectrometric discrimination by 
thin-layer chromatography (TLC), gas chromatography (GC), 
GC-MS and FTIR for a number of fentanils are discussed by 
Ohta et al. (Ohta et al., 1999).
It is important to note that GC-MS analysis of 
4-fluoroisobutyrylfentanyl (4F-iBF) and 4-fluoro-butyrfentanyl 
(4F-BF) display very similar mass spectrometry fragmentation 
patterns. The ability to distinguish between both isomers 
requires the use of analytical reference standards or access to 
reference spectra for both substances.
It is possible that commonly used screening methods for 
fentanyl (i.e., ELISA) may not distinguish between 
4-fluoroisobutyrylfentanyl and fentanyl due to the structural 
similarity between the two substances (US DEA, 2017). 
Identification of 4-fluoroisobutyrylfentanyl might therefore 
require further confirmatory analysis, such as mass 
spectrometry (US DEA, 2017). Similarly, 
4-fluoroisobutyrylfentanyl is not expected to give a positive 
response to tests developed for morphine-type opioids. There 
is no information on the reaction of 4-fluoroisobutyrylfentanyl 
to presumptive colour tests.
 3.2  Information on the frequency, circumstances 
and/or quantities in which a new psychoactive 
substance is encountered, and information on the 
means and methods of manufacture of the new 
psychoactive substance (Article 5.2(b) of the 
Council Decision)
The data reported to Europol discussed in section 3.2.1 may 
overlap with the data reported to the EMCDDA discussed in 
section 3.2.2.
3.2.1 Information provided to Europol
Europol received replies from 16 Member States (Austria, 
Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Finland, 
Germany, Greece, Latvia, Lithuania, Luxembourg, Romania, 
Slovakia, Slovenia and Spain).
Thirteen countries reported that they have no available 
information on 4-fluoroisobutyrylfentanyl (Austria, Bulgaria, 
Croatia, Cyprus, Czech Republic, Finland, Greece, Latvia, 
Lithuania, Luxembourg, Romania, Slovakia and Spain).
Three countries provided information on 
4-fluoroisobutyrylfentanyl (Belgium, Germany and Slovenia). 
Slovenia provided information on a collected sample 
(section 3.2.2).
The level of production
No information was received in relation to the production of 
4-fluoroisobutyrylfentanyl.
The level of distribution
Two small seizures in powder form, of 6 g each, were reported 
by Belgium and Germany.
The level of trafficking
No information was received in relation to the trafficking of 
4-fluoroisobutyrylfentanyl.
3.2.2 Information provided to the EMCDDA
The EMCDDA received responses from 27 Member States (5), 
as well as from Turkey and Norway. Of these, five Member 
States (Belgium, Germany, Slovenia, Sweden and the United 
Kingdom) reported detections of 4-fluoroisobutyryl fen-
tanyl (10, 11).
It is important to note that detections of 4-fluoroisobutyrylfen-
tanyl may be under-reported since the substance is not 
routinely screened for. Three Member States (Austria, Slovenia 
and Sweden) and Norway reported that 4-fluoroisobutyryl-
fentanyl is part of routine screening in some (but not all) 
laboratories.
Seizures
In total, 23 seizures of 4-fluoroisobutyrylfentanyl were 
reported to the EMCDDA by four Member States: Sweden 
(20 seizures), Belgium (1), Germany (1) and the United 
Kingdom (1). The seizures comprise both police and customs 
cases. A majority of the seizures took place in 2016, while the 
most recent events took place in 2017.
(10) ‘Detections’ is an all-encompassing term and may include seizures and/or 
collected and/or biological samples that are analytically confirmed. Seizure 
means a substance available (seized) through law enforcement activities (police, 
customs, border guards, etc.). Collected samples are those that are actively 
collected by drug monitoring systems (such as test purchases) for monitoring 
and research purposes. Biological samples are those from human body fluids 
(urine, blood, etc.) and/or specimens (tissues, hair, etc.). 
(11) Finland reported a seizure of 0.05 g of a powder which was reported as  
‘2F-, 3F- or 4F-BF; 2F-, 3F- or 4F-iBF’, as the exact isomer was not be determined. 
This case is not discussed further in this report.
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Seizures of 4-fluoroisobutyrylfentanyl included:
 ¡ 12 seizures of tablets, all reported by Sweden, amounting 
to a total of 6 727 tablets;
 ¡ 8 seizures of powders (Belgium, Germany, Sweden and the 
United Kingdom) amounting to a total of 272 g;
 ¡ 3 seizures of liquids, all reported by Sweden, amounting to 
a total of 208 mL.
The powder seizure reported by Germany also contained 
furanylfentanyl and the powder seizure from the United 
Kingdom also contained fluorofentanyl (no isomer specified) 
and furanylfentanyl. For the remaining seizures, there is no 
information on whether other substances were also detected. 
No quantitative information on purity was reported.
The final destination of the seizure made in Belgium was 
Germany.
Collected samples
One collected sample was reported by Slovenia, which 
consisted of 5 g of powder test-purchased from the internet 
from a site based in China. No other substances were 
detected in the sample.
Biological samples
Serious adverse events with confirmed exposure to 
4-fluoroisobutyrylfentanyl from biological samples are 
discussed in section 3.4.2.
 3.3  Information on the involvement of organised 
crime in the manufacture or trafficking of the new 
psychoactive substance (Article 5.2(c) of the 
Council Decision)
No information concerning the involvement of organised crime 
in the manufacture and/or trafficking of the 
4-fluoroisobutyrylfentanyl was provided.
Money laundering aspects
No information was received on money laundering in 
connection with the production and/or trafficking of 
4-fluoroisobutyrylfentanyl.
Violence in connection with production, wholesale and 
distribution
No information was received on incidents of violence in 
connection with the production, wholesale and/or trafficking 
of 4-fluoroisobutyrylfentanyl.
 3.4  A first indication of the risks associated with the 
new psychoactive substance, including the health 
and social risks, and of the characteristics of 
users — Article 5.2(d) of the Council Decision
3.4.1 Health risks
Pharmacology and toxicology
Limited data suggests that 4-fluoroisobutyrylfentanyl is 
a μ-opioid receptor agonist that shares some similarities with 
opioid analgesics such as morphine and fentanyl (US DEA, 
2017).
The acute effects of these types of opioids include: euphoria, 
relaxation, analgesia, sedation, bradycardia, hypothermia and 
respiratory depression. They also have an abuse liability and 
dependence potential (Herz, 1993; Kieffer, 1999, Pasternak 
and Pan, 2013; Pattinson, 2008; Romberg et al., 2003).
Similar to other opioid analgesics, the most serious acute 
health risk from using 4-fluoroisobutyrylfentanyl is probably 
respiratory depression, which in overdose could lead to 
apnoea, respiratory arrest and death (EMCDDA, 2017b; 
Pattinson, 2008; White and Irvine, 1999). This risk may be 
greater due to: the difficulty in diluting the substance; a lack of 
experience with its effects and dosing; the use of other central 
nervous system depressants at the same time (such as other 
opioids, benzodiazepines, gabapentanoids and alcohol); a lack 
of tolerance to opioids; and, using the substance alone (such 
as at home) which would make it more difficult for users to call 
for help in the case of poisoning.
The antidote naloxone should reverse acute poisoning caused 
by 4-fluoroisobutyrylfentanyl (Kim and Nelson, 2015; Ujváry et 
al., 2017). Recent clinical and community experience in treating 
poisonings caused by fentanils suggests that larger than 
normal doses and repeated doses of naloxone may be required 
to fully reverse poisoning in some cases (EMCDDA, 2017b).
While there is limited data for 4-fluoroisobutyrylfentanyl, the 
chronic health risks might share some similarities to opioids such 
as heroin and other fentanils. This may include dependence.
3.4.2 Serious adverse events
Acute intoxications reported to the EMCDDA
No acute intoxication with confirmed exposure to 
4-fluoroisobutyrylfentanyl were reported (12).
(12) Sweden reported two acute intoxications with suspected exposure to 
4-fluoroisobutyrylfentanyl. These cases are not discussed further in this report.
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Deaths reported to the EMCDDA
In total, 16 deaths with confirmed exposure to 
4-fluoroisobutyrylfentanyl were reported by Sweden (13, 14). 
The cases occurred between 2016 and 2017.
Of the deaths, 14 were male (88 %) and two were female 
(12 %). The males were aged between 24 and 52 years (mean 
36, median 36); the females were aged 24 and 36 years. 
A range of other substances were detected in the deaths, 
including other central nervous system depressants. Other 
opioids were only detected in five cases. Where known, many 
of the individuals were found dead in a home environment. In 
at least 11 cases, 4-fluoroisobutyrylfentanyl was the cause of 
death or contributed to the death.
3.4.3 Characteristics of users
Similar to other new fentanils, 4-fluoroisobutyrylfentanyl is 
sold and used a ‘legal’ substitute for illicit opioids and 
prescription opioids; this may include for self-medication, 
such as the alleviation of pain and/or opioid withdrawal. Users 
may include high-risk drug users as well as others (such as 
psychonauts) who may be experimenting with the substance.
3.4.4 Social risks
While there is limited data for 4-fluoroisobutyrylfentanyl, the 
social risks might share some similarities with opioids such as 
heroin and other fentanils.
Of additional note is that, in the past few years, fentanils have 
been sold in Europe as ready-to-use nasal sprays and e-liquids 
for vaping. In general, these novel products could make it 
easier to use such substances (with similar effects to 
injecting) and make them more socially acceptable.
Similar to other fentanils, accidental exposure to 
4-fluoroisobutyrylfentanyl may also pose a risk of severe 
poisoning. Those at risk may include the family and friends of 
users, law enforcement, emergency personnel, medical and 
forensic laboratory personnel, as well as those working in the 
postal services. Where required, these risks should be 
assessed and appropriate procedures, training and protective 
measures should be implemented. This may include training in 
resuscitation and adequate provision of the antidote naloxone.
(13) One of the deaths had been previously included in the recent Joint Report 
and risk assessment of acryloylfentanyl (EMCDDA, 2016 and 2017a).
(14) The United Kingdom reported a total of four deaths in which confirmation of 
4-fluoroisobutyrylfentanyl is currently pending. These cases are not discussed 
further in this report.
 3.5  Information on whether or not the new substance 
is currently under assessment, or has been under 
assessment, by the UN system (Article 5.2(e) of 
the Council Decision)
The World Health Organization is the specialised United 
Nations agency designated for the evaluation of the medical, 
scientific and public health aspects of psychoactive 
substances under the Single Convention on Narcotic Drugs, 
1961 and the Convention on Psychotropic Substances, 1971.
On 1 May 2017, the World Health Organization informed the 
EMCDDA that 4-fluoroisobutyrylfentanyl is currently not under 
assessment and has not been under assessment by the UN 
system.
Since then, the World Health Organization has published a list 
of substances that will be reviewed at the 39th meeting of the 
WHO Expert Committee on Drug Dependence (ECDD) that 
will be held in November 2017. 4-Fluoroisobutyrylfentanyl was 
included in the list of substances that will be reviewed. At the 
time of writing this report neither a critical review nor a written 
recommendation had been published.
 3.6  The date of notification on the Reporting Form of 
the new psychoactive substance to the EMCDDA 
or to Europol (Article 5.2(f) of the 
Council Decision)
The first official EMCDDA–Europol notification of 
4-fluoroisobutyrylfentanyl dates from 26 August 2016 from 
the Slovenian national focal point. The Reporting Form details 
the identification of 4-fluoroisobutyrylfentanyl in 5 g of white 
powder in a collected sample which was test-purchased by 
the Slovenian National Forensic Laboratory as part of the EU 
co-funded project RESPONSE, on 25 May 2016 in Ljubljana. 
The sample was shipped from China. The substance was 
analytically confirmed by GC-MS, HPLC-TOF, FTIR-ATR, 
GC-MS-IR (condensed phase), ion chromatography and NMR 
by the Slovenian National Forensic Laboratory and the Faculty 
of Chemistry and Chemical technology of the University of 
Ljubljana.
4-Fluoroisobutyrylfentanyl was added to the list of new 
psychoactive substances monitored by the EMCDDA and 
Europol through the European Union Early Warning System. 
A profile of the substance was created on the European 
Database on New Drugs (EDND). Since then, analytical details 
and other information, including a public health alert, have been 
exchanged between the EMCDDA, Europol and the Member 
States, Turkey and Norway, on an ad hoc basis; the European 
Commission and the EMA have been kept duly informed.
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It is important to note that 4-fluoroisobutyrylfentanyl was first 
identified in a seizure in Germany in November 2016. 
4-Fluoroisobutyrylfentanyl was identified in 6.176 g of white 
powder by German Police in Berlin. Of note was that the 
powder was also found to contain furanylfentanyl.
 3.7  Information on whether or not the new 
psychoactive substance is already subject to 
control measures at national level in a Member 
State (Article 5.2(g) of the Council Decision)
Six Member States (Cyprus, Estonia, Latvia, Lithuania, Sweden 
and the United Kingdom) reported that 4-fluoroisobutyrylfentanyl 
is controlled under drug control legislation.
Two Member States (Austria and Poland) reported that 
4-fluoroisobutyrylfentanyl is controlled under specific new 
psychoactive substances control legislation.
Nineteen Member States (Belgium, Bulgaria, Croatia, Czech 
Republic, Denmark, Finland, France, Germany, Greece, 
Hungary, Ireland, Italy, Luxembourg, Malta, the Netherlands, 
Portugal, Romania, Slovenia and Spain) and Turkey reported 
that 4-fluoroisobutyrylfentanyl is not subject to control 
measures at the national level.
Norway reported that it is not known whether 
4-fluoroisobutyrylfentanyl is controlled, as the substance is 
not covered by any of the generic groups defined in the drug 
control legislation. It may be covered by the medicinal 
products legislation if its effects are proved by scientific 
evidence.
Slovakia did not provide information on the control status of 
4-fluoroisobutyrylfentanyl.
 3.8  Further information (Article 5.2(h) of the 
Council Decision)
3.8.1  The chemical precursors that are known to have 
been used for the manufacture of the substance
No information was reported by the Member States, Turkey or 
Norway, about the chemical precursors or manufacturing 
methods used to make the 4-fluoroisobutyrylfentanyl which 
has been detected within Europe.
The synthesis of 4-fluoroisobutyrylfentanyl was first described 
in 1999 (Ohta et al., 1999). 4-Fluoroisobutyrylfentanyl and 
23 other fentanyl-related compounds were synthesised by 
Van Bever et al. (Van Bever et al., 1974).
The manufacture of 4-fluoroisobutyrylfentanyl relies on 
precursors and synthetic methods similar to those used for 
the manufacture of pharmaceutical fentanyl (Casy and 
Huckstep, 1988; Gupta et al., 2013; Zee and Wang, 1980). 
Therefore the methods developed for the synthesis of fentanyl 
are applicable to the synthesis of 4-fluoroisobutyrylfentanyl. 
Use of a different acylating agent in the final acylation step, 
such as isobutyryl chloride would produce 
4-fluoroisobutyrylfentanyl. A one-step method uses N-phenyl-
1-(2-phenylethyl)piperidin-4-amine (4-ANPP) and isobutyryl 
chloride for the manufacture of the substance.
Two potential precursors of fentanyl and other fentanils 
4-ANPP as well as N-phenethyl-4-piperidone (NPP), a pre-
precursor have been recently scheduled under the United 
Nations Convention against Traffic in Narcotic Drugs and 
Psychotropic Substances, 1988 (15).
Most of the synthetic procedures are straightforward, use 
common laboratory equipment and precursors and detailed 
recipes are available on the internet (16). While only basic 
knowledge of synthetic chemistry is required, due to the 
potency of fentanils extreme caution is required when carrying 
out the final synthetic step as well as when purifying and 
handling the substance (17). Exposure of the skin and mucous 
membranes to fentanils as well as their inhalation pose 
a serious risk of accidental poisoning. In addition to exercising 
extreme caution, suitable personal protective equipment as 
well as sufficient stocks of naloxone as an antidote to 
poisoning following accidental exposure should be available 
when handling materials suspected to contain these 
substances (CDCP, 2013; US DEA, 2016).
In summary, the synthesis of 4-fluoroisobutyrylfentanyl has 
been described in the literature. Other routes developed for 
the production of fentanyl may also be used for the 
manufacture of 4-fluoroisobutyrylfentanyl. There is no 
information on the actual method(s) used for the production 
of 4-fluoroisobutyrylfentanyl that has been detected in Europe 
to date.
(15) Table I of the United Nations Convention against Traffic in Narcotic Drugs and 
Psychotropic Substances, 1988.
(16) The detailed description of the most common procedure, referred to as the 
‘Siegfried method’, is readily available on the internet (see, for example,  
http://opioids.com/fentanyl/synthesis.html).
(17) Self-educated clandestine chemists commented on the risk while discussing 
the synthesis of fentanyl and its potent 3-methyl and α-methyl homologues 
(comment was posted on 7 May, 2002); available at: https://the-hive.archive.
erowid.org/forum/showflat.pl?Cat=&Number=260275 (Accessed: 27 June 2017).
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3.8.2  The mode and scope of the established or 
expected use of the new substance
No studies were identified that have examined the mode and 
scope of established or expected use of 4-fluoroisobutyrylfentanyl. 
Given the limited information currently available, the relevant 
information has been included in the previous sections.
3.8.3  Other use of the new psychoactive substance 
and the extent of such use, the risks associated 
with this use of the new psychoactive 
substance, including the health and social risks
No information was provided by the Member States, Turkey or 
Norway that indicated that 4-fluoroisobutyrylfentanyl had any 
other use apart from in analytical reference materials and 
scientific research.
From the available information, it does not appear that 
4-fluoroisobutyrylfentanyl is used in the manufacture of 
a medicinal product in the European Union. However, the data 
collection is incomplete and some countries indicated that 
this information is not known. It is understood that the 
collection of such information is a challenge in the absence of 
a database on the synthetic route of all medicinal products.
Ten countries (Austria, Belgium, Croatia, Denmark, Greece, 
Italy, the Netherlands, Poland, Spain and the United Kingdom) 
reported that 4-fluoroisobutyrylfentanyl is not used to 
manufacture a medicinal product for human use. Nine 
countries (Czech Republic, Estonia, Finland, Germany, 
Hungary, Ireland, Latvia, Norway and Sweden) reported that it 
was unknown if 4-fluoroisobutyrylfentanyl is used to 
manufacture a medicinal product for human use.
In addition, the EMA reported that it is not known if 
4-fluoroisobutyrylfentanyl is used in the manufacture of 
medicinal products for human use and which are centrally 
authorised within the European Union.
Ten countries (Austria, Belgium, Denmark, France, Greece, 
Latvia, Poland, Slovakia, Spain and the United Kingdom) 
provided information that 4-fluoroisobutyrylfentanyl is not 
used to manufacture a medicinal product for veterinary use. 
Eight countries (Estonia, Finland, Germany, Ireland, Norway, 
Portugal, Slovenia and Sweden) reported that it was unknown 
if 4-fluoroisobutyrylfentanyl is used to manufacture 
a medicinal product for veterinary use.
In addition, the EMA reported that it is not known if 
4-fluoroisobutyrylfentanyl is used in the manufacture of 
medicinal products for veterinary use and which are centrally 
authorised within the European Union.
 4.  Information from the EMA (Article 5.3 
of the Council Decision)
Nineteen countries (Austria, Belgium, Croatia, Czech Republic, 
Denmark, Estonia, Finland, Germany, Greece, Hungary, 
Ireland, Italy, Latvia, the Netherlands, Norway, Poland, Spain, 
Sweden and the United Kingdom) reported that:
 ¡ 4-fluoroisobutyrylfentanyl has not been granted 
a marketing authorisation as a medicinal product for human 
use;
 ¡ 4-fluoroisobutyrylfentanyl is not the subject of an 
application for a marketing authorisation as a medicinal 
product for human use;
 ¡ there had been no cases of suspended marketing 
authorisation in respect to 4-fluoroisobutyrylfentanyl as 
a human medicine.
Eighteen countries (Austria, Belgium, Denmark, Estonia, 
Finland, France, Germany, Greece, Ireland, Latvia, Norway, 
Poland, Portugal, Slovakia, Slovenia, Spain, Sweden and the 
United Kingdom) reported that:
 ¡ 4-fluoroisobutyrylfentanyl has not been granted 
a marketing authorisation as a medicinal product for 
veterinary use;
 ¡ 4-fluoroisobutyrylfentanyl is not the subject of an 
application for a marketing authorisation as a medicinal 
product for veterinary use;
 ¡ there had been no cases of suspended marketing 
authorisation in respect to 4-fluoroisobutyrylfentanyl as 
a veterinary medicine.
The EMA also reported that 4-fluoroisobutyrylfentanyl:
 ¡ has not been granted a marketing authorisation as 
a medicinal product for neither human nor veterinary use 
through the centralised procedure;
 ¡ is not the subject of an application for a marketing 
authorisation for neither human nor veterinary use through 
the centralised procedure;
 ¡ is not the subject of a suspended marketing authorisation 
for neither human nor veterinary use through the 
centralised procedure.
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I 5. Conclusion
4-Fluoroisobutyrylfentanyl belongs to a group of synthetic 
opioids known as the fentanils. It is closely related to fentanyl, 
which is controlled under the United Nations Single 
Convention on Narcotic Drugs, 1961. Data suggests that 
4-fluoroisobutyrylfentanyl may be an opioid narcotic analgesic 
in humans and, as such, may have an abuse liability and 
dependence potential; overall, these effects may be broadly 
comparable to fentanyl. The most serious acute health risk 
posed by 4-fluoroisobutyrylfentanyl is likely to be respiratory 
depression, which in overdose is life-threatening. The antidote 
naloxone should reverse acute poisoning.
4-Fluoroisobutyrylfentanyl has been available in the European 
Union since at least July 2016. It has been detected in four 
Member States where it has been seized as a powder, tablets 
and liquids. The detected quantities are relatively small; 
however, they should be seen within the context of the high 
potency that is typical of the fentanils.
There are indications that the 4-fluoroisobutyrylfentanyl 
currently available on the market is synthesised by chemical 
companies based in China. 4-Fluoroisobutyrylfentanyl is sold 
online often under the guise of a ‘research chemical’. It is 
available in wholesale amounts and in consumer amounts.
Sixteen deaths with confirmed exposure to 
4-fluoroisobutyrylfentanyl have been reported by one Member 
State. In at least 11 of the deaths, 4-fluoroisobutyrylfentanyl 
was the cause of death or contributed to the death.
4-Fluoroisobutyrylfentanyl is sold and used a substitute for 
illicit opioids and prescription opioids. Similar to other 
fentanils, serious concerns exist that the substance could be 
supplied surreptitiously to a range of drug users.
4-Fluoroisobutyrylfentanyl is under assessment within the 
United Nations system. It will be reviewed at the 39th meeting 
of the WHO Expert Committee on Drug Dependence (ECDD) 
that will be held in November 2017. Currently, neither a critical 
review nor a written recommendation has been published. 
4-Fluoroisobutyrylfentanyl is not subject to control measures 
in 19 Member States and Turkey.
We conclude that the health and social risks caused by the 
manufacture, trafficking and use of 4-fluoroisobutyrylfentanyl 
and the involvement of organised crime and possible 
consequences of control measures, could be thoroughly 
assessed through a risk assessment procedure in accordance 
with Article 6 of Council Decision 2005/387/JHA.
The EMCDDA and Europol will continue to intensively monitor 
4-fluoroisobutyrylfentanyl in order to ensure that new 
information is provided to the Member States, the EMA and 
the Commission via the information exchange of the European 
Union Early Warning System.
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